Dendreon's press releases over the past year are seemingly filled with nothing but bad news. Investors suffered another gut punch today, as shares plummeted 23% amid declining Provenge sales -- but also in the face of a significant operational shake-up that should let the company more easily break even. Watch health-care editor and analyst David Williamson break down what these events mean for investors.
Many investors are attracted to biotechs like Dendreon, since they hold the allure of substantial short-term gains. But there is more than one approach to building long-term wealth and retiring well. In our free report "3 Stocks That Will Help You Retire Rich," we reveal some stocks that could help you as well as some winning wealth-building strategies. Click here to keep reading.